Metastatic Ovarian Carcinoma Clinical Trials
20 clinical trials for Metastatic Ovarian Carcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours — RECRUITING · PHASE1
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer — RECRUITING · PHASE1
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer — RECRUITING · PHASE1
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
- CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors — RECRUITING · PHASE2
- Paclitaxel Therapeutic Drug Monitoring in Cancer Patients — SUSPENDED
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2
- Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Prediction of Ovarian Cancer Histotypes and Surgical Outcome — NOT_YET_RECRUITING
- A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors — TERMINATED · PHASE1
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis — COMPLETED · PHASE1
- Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma — TERMINATED · PHASE2
- Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer — COMPLETED · PHASE1
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer — WITHDRAWN · PHASE1
Refine this search